Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | ESRRB | O95718 | 1/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043161 | 1.00 | TLR8 (0.51) | TLR8MAPTGAAATMMEN1 | |
| Ammonia Solution, Strong SCHEMBL27616951 | 0.98 | TLR8 (0.50) | TLR8MAPTGAAATMMEN1 | |
| SCHEMBL29729491 | 0.84 | ESR1 (0.50) | TLR8MAPTGAAATMMEN1 | |
| SCHEMBL6162407 | 0.84 | ESR1 (0.50) | TLR8MAPTGAAATMMEN1 | |
| Bromide SCHEMBL9069911 | 0.82 | ESR1 (0.49) | TLR8MAPTGAAATMMEN1 | |
| SCHEMBL29396540 | 0.79 | NR4A2 (0.66) | TLR8MAPTGAAATMMEN1 | |
| SCHEMBL317202 | 0.79 | NR4A2 (0.66) | TLR8MAPTGAAATMMEN1 | |
| SCHEMBL29509132 | 0.79 | TLR8 (0.54) | TLR8MAPTGAAATMMEN1 | |
| SCHEMBL28164080 | 0.79 | TLR8 (0.54) | TLR8MAPTGAAATMMEN1 | |
| SCHEMBL22461265 | 0.78 | TLR8 (0.50) | TLR8MAPTGAAATMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | MBD Co., Ltd. (KR) | 2024-08-29 | — | — | US | disclosed |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-30 | — | — | US | disclosed |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-09 | — | — | US | disclosed |
| WO-2022235091-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | 엠비디 주식회사 | 2022-11-10 | — | — | WO | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | CYP4B1, CYP4A11, CYP3A4 | TLR8 2603/4885MAPT 3959/4885GAA 324/4885 |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | TLR8 4455/4885MAPT 2607/4885GAA 2961/4885 |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | TLR8 3906/4885MAPT 2774/4885GAA 3005/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | TLR8 4520/4885MAPT 2797/4885GAA 940/4885 |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | TLR8 3787/4885MAPT 2816/4885GAA 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.